Tectonic Therapeutic, Inc. TECX
Set alert
19.78 USD -0.72 -3.51%
At close · Oct 30
19.78 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
19.56 Day range 20.51
16.44 52-week range 37.93
- YTD
- -5.18%
- 1 year
- +12.39%
- Open
- 20.51
- Prev close
- 20.50
- Mkt cap
- 386.69M
- Vol
- 146.26K
- Avg vol
- 220.74K
- EPS
- -4.57
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.56
- High
- 20.51
- Forward P/E
- -10.16
- Beta
- 0.00
- Short ratio
- 3.54
- Inst. own
- 46.91%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 43.40
- 200-d avg
- 24.05
- 1y target
- 74.67
6M chart
Signals (32)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 8, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 2, 2026 | 1 month ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| RSI: Overbought | Jul 2, 2026 | 4 months ago |
| RSI: Overbought | Jun 30, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 9, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 14, 2026 | 5 months ago |
| MACD: Sell Signal | May 7, 2026 | 5 months ago |
| SMA: Bearish | May 5, 2026 | 5 months ago |
| MACD: Buy Signal | May 5, 2026 | 5 months ago |
| SMA: Bullish | May 1, 2026 | 6 months ago |
Key statistics
- Market cap
- 701.64M
- Enterprise value
- 517.32M
- Trailing P/E
- 0.00
- Forward P/E
- -10.16
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.21
- EPS (TTM)
- -3.07
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 185.12M
- Total debt
- 3.44M
- Return on equity
- 0.00%
- Shares outstanding
- 14.75M
- Short % of float
- 0.00%
- 50-day average
- 43.40
- 200-day average
- 24.05
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 74.67 +277.5% upside
Now 19.78
- Target (low)
- 69.00
- Target (mean)
- 74.67
- Target (high)
- 79.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
TECX Revenue — quarterly 0
TECX Net income — quarterly -22.29M
TECX EPS — quarterly -1.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.84 | -1.20 | -0.36 | -42.86% |
| Aug 14, 2024 | Jun 1, 2024 | -1.96 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -1.96 | -3.81 | -1.85 | -94.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Raymond James | init | — | Outperform |
| Nov 12, 2024 | Wells Fargo | main | Overweight | Overweight |
| Nov 11, 2024 | Leerink Partners | main | Outperform | Outperform |
| Aug 22, 2024 | Wells Fargo | init | — | Overweight |
| Jul 24, 2024 | Leerink Partners | init | — | Outperform |
| Jun 26, 2024 | Piper Sandler | init | — | Overweight |
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tectonictx.com
News
- Tectonic Therapeutic, Inc. (TECX) – What Are Researchers Thinking About This Stock?
- UBS Initiates Coverage On Tectonic Therapeutic with Neutral Rating, Announces Price Target of $26
- Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
- Tectonic Therapeutic, Inc. (NASDAQ:TECX) Stock Has Average Price Target of $77.25 According to Analysts
- Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
- Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case
- Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $93
- Tectonic Therapeutic Q2 EPS $(1.18) Beats $(1.37) Estimate
- Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
- Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Your note
Sign in to keep a note on TECX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CORTIS CHRISTIAN | Chief Operating Officer | Stock Award(Grant) | Jun 19, 2024 | 126,368 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 13, 2024 | 0 |
| MCGUIRE TERRANCE G | Director | Stock Award(Grant) | Jun 19, 2024 | 0 |
| MCNAMARA PETER | Officer | Conversion of Exercise of derivative security | Dec 2, 2024 | 14,188 |
| REICIN ALISE S | Chief Executive Officer | Stock Award(Grant) | Dec 3, 2024 | 302,827 |
| RUDDY MARCELLA KUHLMAN M.D. | Officer | Stock Award(Grant) | Jun 19, 2024 | 32,065 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 8.27% | 1,220,138 | 58.03M | Sep 29, 2024 |
| Vida Ventures Advisors, LLC | 6.97% | 1,028,674 | 48.92M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 5.76% | 849,143 | 40.39M | Sep 29, 2024 |
| 5AM Venture Management, LLC | 4.38% | 646,524 | 30.75M | Sep 29, 2024 |
| Farallon Capital Management LLC | 3.53% | 520,397 | 24.75M | Sep 29, 2024 |
| Vanguard Group Inc | 3.00% | 442,814 | 21.06M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.59% | 381,589 | 18.15M | Sep 29, 2024 |
| Fidelity Advisor Biotechnology Fund | 0.97% | 142,600 | 6.78M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.30% | 44,790 | 2.13M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.26% | 38,226 | 1.82M | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.13% | 18,948 | 901.17K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.13% | 18,564 | 882.90K | Oct 30, 2024 |